| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 157,00 | 157,95 | 12:56 | |
| 157,00 | 157,95 | 11:21 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 168,80 | 20 | |||
| 162,85 | 150 | |||
| 161,60 | 1.300 | |||
| 161,55 | 55 | |||
| 160,80 | 150 | |||
| 160,65 | 300 | |||
| 159,80 | 80 | |||
| 159,60 | 2 | |||
| 159,50 | 117 | |||
| 159,15 | 29 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 66 | 155,35 | |||
| 65 | 155,30 | |||
| 2 | 155,00 | |||
| 72 | 153,95 | |||
| 40 | 153,65 | |||
| 72 | 152,25 | |||
| 55 | 152,05 | |||
| 1.350 | 152,00 | |||
| 1.300 | 151,20 | |||
| 300 | 150,50 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.322 | 0,663 | 2.203 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 23.03.2026 | 15:38:33 | 157,70 | 214 |
| 23.03.2026 | 14:30:59 | 158,80 | 63 |
| 23.03.2026 | 14:30:59 | 158,80 | 220 |
| 23.03.2026 | 14:30:59 | 158,80 | 214 |
| 23.03.2026 | 14:30:23 | 158,30 | 110 |
| 23.03.2026 | 14:30:23 | 158,30 | 46 |
| 23.03.2026 | 14:30:15 | 158,30 | 60 |
| 23.03.2026 | 14:30:15 | 158,30 | 54 |
| 23.03.2026 | 11:06:25 | 156,65 | 2 |
| 23.03.2026 | 10:23:34 | 156,25 | 30 |
| 23.03.2026 | 10:23:33 | 156,25 | 54 |
| 23.03.2026 | 10:23:33 | 156,30 | 2 |
| 23.03.2026 | 10:23:33 | 156,25 | 94 |
| 23.03.2026 | 09:04:36 | 151,30 | 7 |
| 23.03.2026 | 09:04:33 | 150,55 | 16 |
| 23.03.2026 | 09:04:33 | 151,65 | 5 |
| 23.03.2026 | 09:04:33 | 151,65 | 49 |
| 23.03.2026 | 09:04:33 | 155,20 | 1 |
| 23.03.2026 | 09:04:33 | 155,20 | 4 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | 720 | GlobeNewswire (Europe) | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| Fr | Eli Lilly, Biogen/Eisai win U.K. review for use of Alzheimer's drugs in NHS | 9 | Seeking Alpha | ||
| Do | Biogen to present litifilimab data for cutaneous lupus at AAD | 3 | Investing.com | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Do | Biogen Inc.: Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting | 422 | GlobeNewswire (Europe) | Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Designation... ► Artikel lesen | |
| 11.03. | Biogen: Chefjuristin Susan H. Alexander verlässt das Unternehmen Ende Mai 2026 | 7 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 11:05 | DARWIN AG: Hohe Skalierbarkeit | Aktien-Global-Researchguide | Nach Darstellung der Analysten Cosmin Filker und Matthias Greiffenberger von GBC besitzt die DARWIN AG ein vertikal integriertes Geschäftsmodell, im Rahmen dessen genetische Analysen, datenbasierte... ► Artikel lesen | |
| 11:58 | BioNTech SE: BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer | GlobeNewswire (Europe) | Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates... ► Artikel lesen | |
| 07:06 | Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) | GlobeNewswire (Europe) | Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo... ► Artikel lesen | |
| 11:58 | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | GlobeNewswire (Deutschland) | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| 02:00 | Innovent Biologics: The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China | PR Newswire | 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W.
SAN... ► Artikel lesen |